Mission and objectives


To develop novel, effective and safer therapies for cancer and autoimmune diseases by targeting molecules identified by single-cell OMICS on tissue-resident T lymphocytes, and associated to these pathological states.


To generate new therapeutic mAbs against T cells infiltrating pathological tissues and promoting to neoplastic and autoimmune diseases. Our present objective is to generate therapeutic mAbs against tumor-infiltrating regulatory T lymphocytes (Tregs) for safer cancer immunotherapy.